Biologic drugs are designed to bind to specific targets with extreme precision. They are engineered to stimulate the immune system to react to the presence of a problem. Biologics are transforming the healthcare landscape by offering patients with debilitating diseases a safe and effective treatment option due to their high target specificity and lower off-target toxicities. As targeted therapies, they have brought us much closer to the realization of personalized solutions to our health problems.
There is a significant unmet need worldwide for safe and efficacious biologic therapies to treat society’s most debilitating health conditions including cancer and autoimmune diseases. Clover believes patients with these devastating diseases deserve access to novel therapies, and we work diligently to develop potentially life-saving treatments for people around the globe.
Clover’s Trimer-Tag© targeted immune-oncology programs focus on cancer apoptosis and immune pathways with the development of three programs including SCB-313, SCB-333 and SCB-340.
Clover’s development of biosimilars, as part of the Fc-Fusion protein programs includes biosimilars to etanercept (Enbrel®) and aflibercept. These biosimilars, SCB-808 and SCB-420, target diseases with significant morbidity including rheumatoid arthritis, ankylosing spondylitis, wet age-related macular degeneration (wet AMD) and diabetes mediated edema (DME). These biosimilars are critical in helping communities in China have better access to biologics for these debilitating diseases.
The Fc-Fusion protein portfolio also includes SCB-219, a novel TPOR agonist currently being developed in preclinical stage to treat chemotherapy-induced thrombocytopenia (CIT) and primary immune thrombocytopenia (ITP).